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Abstract A simple wipe sampling procedure was devel-
oped for the surface contamination determination of ten
cytotoxic drugs: cytarabine, gemcitabine, methotrexate,
etoposide phosphate, cyclophosphamide, ifosfamide, irino-
tecan, doxorubicin, epirubicin and vincristine. Wiping was
performed using Whatman filter paper on different surfaces
such as stainless steel, polypropylene, polystyrol, glass,
latex gloves, computer mouse and coated paperboard.
Wiping and desorption procedures were investigated: The
same solution containing 20% acetonitrile and 0.1% formic
acid in water gave the best results. After ultrasonic
desorption and then centrifugation, samples were analysed
by a validated liquid chromatography coupled to tandem
mass spectrometry (LC–MS/MS) in selected reaction
monitoring mode. The whole analytical strategy from wipe
sampling to LC–MS/MS analysis was evaluated to deter-
mine quantitative performance. The lowest limit of quan-
tification of 10 ng per wiping sample (i.e. 0.1 ng cm−2) was
determined for the ten investigated cytotoxic drugs.
Relative standard deviation for intermediate precision was
always inferior to 20%. As recovery was dependent on the
tested surface for each drug, a correction factor was
determined and applied for real samples. The method was
then successfully applied at the cytotoxic production unit of
the Geneva University Hospitals pharmacy.
Keywords Cytotoxic . Antineoplastic drugs . Surface
contamination . Environmental monitoring . LC–MS/MS .
Wipe sampling
Introduction
Cytotoxic drugs are widely used in cancer therapy, and
an increasing number of patients receiving chemotherapy
have been observed during the last decades. These drugs
have been recognized as hazardous for healthcare
professionals such as oncology nurses or pharmacists
and technicians [1]. Despite the existence of safety
standards for handling cytotoxic drugs, several studies
report low-level contamination of these compounds on
workbenches, floors, vials, gloves and storage shelves [2–
10]. Traces of cytotoxic agents have also been found in
urine [11–17] and blood of healthcare professionals [18],
indicating that this working population is at risk. Never-
theless, a direct relationship between exposure to cytotoxic
contamination and harmful effects has not been estab-
lished yet, and no maximal acceptable amount of surface
contamination for these drugs has been set up by
regulatory offices until now. According to precautionary
principles, exposure should nevertheless be kept at the
lowest possible level [19]. Monitoring of contamination is
essential to ascertain the contamination risk in order to
improve working conditions by effective cleaning proce-
dures or other measures.
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In Germany, threshold guidance values for platinum and
5-fluorouracil have been set on the basis of data from a
large multicenter study including 102 pharmacies [20, 21].
Wiping samples have been obtained by compound-specific
wiping procedures and analysed by voltammetry for
platinum drugs and by GC-MS for fluorouracil. This
approach presented very good quantitative performance
and detection limits (i.e., 0.1–1 pg per sample) and
estimated potential surface contamination using platinum
drugs or 5-FU as model markers. However, a wide range of
chemotherapy formulations with different drugs and with
different preparation procedures are produced daily in
hospital cytotoxic units. To get an overview of several
contaminations, multi-compound methods are required. To
the author’s knowledge, only few generic wiping proce-
dures have been developed, for example a wipe sampling
procedure coupled to liquid chromatography–tandem mass
spectrometry (LC–MS/MS) for the simultaneous determi-
nation of gemcitabine, paclitaxel, cyclophosphamide and
ifosfamide [22] or for methotrexate, 5-fluorouracil and
cyclophosphamide [9]. Other toxic compounds, such as
irinotecan, anthracyclines or vincalcaloïdes, which are also
largely used in chemotherapies, have rarely been included
in surface contamination studies.
Recently, we developed and validated a LC–MS/MS
method for the simultaneous quantification of ten cytotoxic
drugs [23]. In the continuity of this method, we present the
development of a wiping and extraction procedure of the
same ten cytotoxic drugs on different surfaces and their
quantitative analysis by the LC–MS/MS method. This wipe
sampling procedure was then applied to evaluate the
surface contamination in the cytotoxic production unit at
the pharmacy of Geneva University Hospital (HUG).
Experimental
Chemicals and reagents
The study was performed with the following commercially
available cytotoxic drugs: Campto® (irinotecan, 20 mgmL−1)
and Cytosar® (cytarabine, 20 mg mL−1) were purchased
from Pfizer AG (Zürich, Switzerland); Gemcitabin Teva®
(gemcitabine reconstituted in water at 20 mg mL−1) and
Vincristin Teva® (vincristine, 1 mg mL−1) from Teva Pharma
AG (Aesch, Switzerland); Holoxan (ifosfamid reconstituted
in water at 40 mg mL−1) and Endoxan® (cyclophosphamide
reconstituted in glucose 5% at 20 mg mL−1) from Baxter
AG (Volketswil, Switzerland); Methotrexat Farmos®
(methotrexate, 2.5 mg mL−1) from Orion Pharma (Zug,
Switzerland); Etopophos® (etoposide phosphate reconsti-
tuted in water at 20 mg mL-1) from Bristol-Myers Squibb
SA (Baar, Switzerland); Doxorubine Ebewe® (doxorubicin,
2 mg mL−1) from Ebewe Pharma (Cham, Switzerland); and
Epirubicin Actavis Solution® (epirubicin, 2 mg mL−1) from
Actavis (Regensdorf, Switzerland).
The reconstitution of Etopophos, Gemcitabine Teva and
Holoxan was performed with water for injection, obtained
from Bichsel Laboratories (Interlaken, Switzerland). Glucose
5% for the reconstitution of Endoxan was from Sintetica-
Bioren SA (Couvet, Switzerland). The internal standard (IS)
[13C, 2H3]-methotrexate was purchased from Alsachim
(Illkirch, France).
Wiping and desorption material
The evaluated materials for wipe sampling were filter paper
(Protein SaverTM 903 Card) from Whatman (Dassel,
Germany), filter card DMPK-300 from Ahlstrom (Helsinki,
Finland) and blend wipers TX 612 from Texwipe (Cabuyao,
Philippines).
Desorption was performed in 1.5-mL polyethylene (PE)
safe-lock tubes from Eppendorf AG (Hamburg, Germany).
Equipment
Analyses were carried out with the liquid chromatography
system Accela from Thermo Fisher Scientific Inc. (Waltham,
MA, USA) consisting of a quaternary pump equipped with an
online degasser, an autosampler and a solvent platform. The
chromatographic system was coupled to a triple quadrupole
(TSQ) Quantum Discovery MS from Thermo Fisher Scien-
tific equipped with an Ion Max electrospray ionization (ESI)
interface and operated with Xcalibur software (Thermo Fisher
Scientific). Separations were done on a ZORBAX SB-C18
RR 2.1×100-mm, 3.5-μm column fromAgilent Technologies
(Waldbronn, Germany).
Solutions
Mobile phase solutions
Chromatography was performed using Lichrosolv® HPLC-
grade acetonitrile (ACN) and ultrapure water from Merck
(Darmstadt, Germany) and formic acid (FA) from Biosolve
(Valkenswaard, the Netherlands). The mobile phase used for
chromatography was constituted of three solutions: ultra-
pure water (solution A), ACN (solution B) and FA 1%
(solution C). Washing of the needle and the injection loop
was performed with 5% ACN in water after each injection.
Cytotoxic stock solutions, calibration standard, internal
standard, desorption and wiping samples
All solutions (i.e. drug reconstitutions and sample dilution)
were prepared in appropriate conditions for handling
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hazardous compounds as cytotoxic agents. Moreover, the
development of the wiping procedure was performed with
brand drugs to avoid direct contact of the operator to the
cytotoxic powder and to minimize contamination risk when
preparing the working solutions.
Aliquots of the IS were prepared with a mixture of ACN
and water (75:25, v/v) at 250 μg mL−1 and stored at −22°°C
for 12 months. No sample degradation was observed. Stock
solutions of IS were regularly diluted at 50 ng mL−1 in
ACN 20% with FA 0.1%, and they were stable for at least
2 weeks at 2–8°°C.
A main stock solution containing the ten cytotoxic drugs
was prepared by diluting each compound in water at a
concentration of 20 μg mL−1. This solution was further
diluted to obtain five independent stock solutions at 20, 40,
200, 1,000 and 4,000 ng mL−1 in ACN 20% with FA 0.1%.
For calibration standards (CS), these solutions were diluted
by the IS solution at 50 ng mL−1 to obtain five CS at 1, 2,
10, 50 and 200 ng mL−1. For desorption samples, the
cytotoxic stock solutions were spiked on a wiping paper
and desorbed with 1 mL of the IS solution at 50 ng mL−1.
For wiping samples, 50 μL of cytotoxic stock solutions was
spread over the studied surface (10×10 cm) by an
adjustable volume micropipette, followed by wiping and
desorption with 1 mL of the IS solution at 50 ng mL−1. The
final concentrations of the ten cytotoxic compounds were at
10, 50 and 200 ng mL−1 for desorption and wiping samples.
All samples were immediately stored at 15°°C in the LC
autosampler and analysed within the day.
Analytical conditions
LC–MS/MS method
The LC–MS/MS conditions have been described elsewhere
[23]. Briefly, the mobile phase flow rate was set at
200 μL min−1 using the following gradient elution
programme with a constant concentration of 0.1% FA during
the entire run: 2% of ACN at 0–2 min, 21% of ACN at 2.5–
10 min, 30% of ACN at 13 min, 50% of ACN from 13.5 to
15.5 min and a re-equilibration step to the initial solvent
from 16 up to 21 min. The thermostated autosampler was
maintained at 15°C and the injection volume was 25 μL.
Positive ESI conditions were: capillary temperature set at
325°°C, spray voltage at 4 kV, and sheath and auxiliary gas
(nitrogen) flow rates at 45 and 2 psi, respectively. MS/MS
was acquired in selected reaction monitoring mode in Q1
and Q3. The Q2 collision gas (argon) pressure was set at
1.5 mTorr. Chromatographic data acquisition, peak integra-
tion and quantification were performed using the Xcalibur
software (ThermoQuest, San Jose, CA, USA). Different time
segments were used as reported in Table 1.
Desorption step development
Standard solution of the ten cytotoxic drugs at 1,000 ng mL−1
and the IS at 1,000 ng mL−1 were spotted on wiping papers
to obtain a final amount of 50 ng per sample for each
compound. Then, desorption was performed with different
desorption solutions (FA 0.1%, 20% ACN with 0.1% FA)
and desorption procedures (gentle mixture, ultrasonication
for 5 and 20 min). Before LC–MS/MS analysis, a
centrifugation step at 2,880 RCF for 5 min was performed
to obtain samples without particulate matter such as fibres
from the filter paper. Each desorption procedure was
repeated in triplicate (N=3).
The best desorption procedure was then evaluated with
three series at three concentrations (10, 50 and 200 ng mL−1),
with four repetitions each. Cytotoxic solutions at 200,
1,000, 4,000 ng mL−1 were spiked on the filter paper to
obtain 10, 50 and 200 ng per sample, put in a PE tube, and
1 mL of the desorption solution (20% ACN with 0.1% FA)
Time segment
(min)
Drug Parent
(m/z)
Product
(m/z)
Collision energy
(eV)
Mean RT
(min)
0–4 Cytarabine 244.0 112.3 15 1.6
Gemcitabine 264.7 112.3 20 1.6
4–7 Methotrexate 455.2 308.0 20 6.0
[13C,2H3] methotrexate 459.2 312.2 20 6.0
7–10 Etoposide phosphate 691.0 691.0 15 7.5
10–13 Ifosfamide 261.1 92.3; 140.2 20 11.4
154.1, 232.9
Cyclophosphamide 261.1 92.3; 140.2 20 12.2
154.1, 232.9
13–14 Irinotecan 587.9 587.3 20 13.7
14–21 Doxorubicin 544.6 379.2, 397.1 15 14.8
Epirubicin 544.6 379.2, 397.1 15 15.3
Vincristine 413.3 353.2 30 15.2
Table 1 Instrument method for
the LC–MS/MS analysis of the
ten cytotoxic drugs with [13C,
2H3]-methotrexate as internal
standard: time segment
description
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containing the IS at 50 ng mL−1 was added. Desorption
was performed by ultrasonication for 20 min followed by
centrifugation at 2,880 RCF for 5 min. Finally, 0.5 mL of
the clear solution was placed in a vial and LC–MS/MS
analysis was performed.
Wiping step development
Standard solutions of the ten cytotoxic drugs at 1,000 ngmL−1
in water were spread over a stainless steel plate (10×10 cm)
with an adjustable volume micropipette to obtain a final
concentration of 0.5 ng cm−2 for each drug. After solvent
evaporation, wiping was performed with three different
wiping papers (Whatman, Ahlstrom and Texwipe). Filter
papers were previously wetted with different wiping sol-
utions (water, NaOH 0.01 M, FA 0.1%, ACN 20% with 0.1%
FA, ACN 50% with 0.1% FA, ACN with 0.1% FA and
isopropyl alcohol 70%) and the tested surface wiped using
tweezers. Each wiping procedure was followed by the
desorption procedure, and LC–MS/MS analysis was repeated
in triplicate (N=3).
Quantitative performance of the method applied to different
surfaces
Quantitative performance was evaluated with the best
wiping and desorption conditions for different surface
types, i.e. stainless steel, polypropylene infusion bags,
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Fig. 1 LC–MS/MS chromatogram of a calibration sample containing
the ten cytotoxic drugs and the internal standard at 50 ng mL−1 in
ACN 20% with 0.1% FA. Column: ZORBAX SB-C18 RR 2.1 ×
100 mm, 3.5 μm; flow rate, 200 μL min−1; gradient conditions are
reported in “Experimental” and scan events are shown in Table 1
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polystyrol bags, glass, latex gloves, computer mouse and
coated paperboard. Solutions containing the ten cytotoxic
drugs at 200, 1,000 and 4,000 ng mL−1 were spiked on a
stainless steel or polypropylene surface to obtain a final
surface concentration of 0.1, 0.5 and 2 ng cm−2. For the
other surfaces, only one concentration (0.5 ng cm−2) was
studied. After solvent evaporation for at least 1 h, wiping
with Whatman filter paper wetted with 0.1 mL of ACN
20% with 0.1% FA was performed. Desorption was carried
out with 1 mL of ACN 20% with 0.1% FA containing the
IS at 50 ng mL−1 by ultrasonication for 20 min and then
centrifugation at 2,880 RCF for 5 min. Finally, 0.5 mL of
the clear solution was placed in a vial, which was followed
by LC–MS/MS analysis.
Evaluation of quantification performance was performed
over three independent series with three repetitions for each
surface and concentration. Each series involved (1) freshly
prepared calibration, wiping samples (corresponding to the
whole procedure: to spread cytotoxic stock solutions on
surfaces, evaporation and dried surface wiping) and
solvents (LC, desorption and wiping solvents); (2) washing
of the column and LC system; (3) LC shut off; (4) cleaning
the capillary and cone of the MS with water and methanol;
and (5) tuning/calibration of the MS system.
Concentrations of the cytotoxic agents were calculated
with reference to a calibration curve constructed the same
day with five levels of CS containing the ten drugs (1, 2,
10, 50 and 200 ng mL−1 in ACN 20% with 0.1% FA) and
weighted linear regression (1/x) for each compound.
Calculations were performed using peak area ratios of the
ten cytotoxic drugs versus the IS.
Stability of cytotoxic drugs on wiping papers
The stability of the cytotoxic drugs on the filter paper was
studied over 3 months. A solution containing the ten
compounds was spiked on the Whatman filter paper and the
papers kept at 25, at 4 and at −22°C. Desorption and LC–MS/
MS analyses were performed in triplicate on day 0, week 1, and
months 2 and 3. Concentrations of the cytotoxic agents were
calculated with reference to a calibration curve constructed the
same day with five levels of CS (1, 2, 10, 50 and 200 ng mL−1
in ACN 20% with 0.1% FA containing the ten drugs) and
weighted linear regression (1/x) for each compound.
Application to surface contamination at the cytotoxic
production unit of HUG pharmacy
For the proof of concept, the developedmethodwas applied to
the measurement of cytotoxic contamination at HUG phar-
macy. Several surfaces of 10×10 cm were tested in the
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mixing 
FA 0.1%: 
ultrasonication 5 min 
FA 0.1%: 
ultrasonication 20 min 
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Fig 2 Desorption step development with Whatman papers: recovery
of cytotoxic drugs as function of different procedures: FA 0.1% with
gentle mixing, FA 0.1% with ultrasonication for 5 min, FA 0.1%
with ultrasonication for 20 min, and 20% ACN, FA 0.1% with
ultrasonication for 20 min
Table 2 Quantitative performance for the desorption of the ten
cytotoxic drugs on Whatman filter paper (50 ng per sample) with
1 mL of ACN 20% with FA 0.1%
Recovery (%) Intermediate precision (%)
Cytarabine 102 5.7
Gemcitabine 99 5.2
Methotrexate 99 1.6
Etoposide phosphate 95 1.9
Ifosfamide 102 7.6
Cyclophosphamide 100 4.9
Irinotecan 102 3.7
Doxorubicin 93 3.9
Epirubicin 94 3.6
Vincristine 98 6.4
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cytotoxic unit, in the preparation and the logistic areas.
However, for some special wiping places such as the door
handle and phone, the wiping surface was reduced for
practical reasons. Concentrations of the cytotoxic drugs were
calculatedwith reference to a calibration curve constructed the
same day with five levels of CS (1, 2, 10, 50 and 200 ng mL−1
in ACN 20% with 0.1% FA containing the ten drugs) and
weighted linear regression (1/x) for each compound. A
correcting factor for each surface and compound was applied
to calculate the surface concentration (see “Quantitative
performance of the method applied to different surfaces”).
Results and discussion
Three steps can be distinguished during the wipe sampling
procedure: (1) wiping of cytotoxic drugs from the investigated
surface to the filter paper; (2) desorption of drugs from the
filter paper to the solution; and (3) LC–MS/MS analysis.
Then, quantitative performance of the whole procedure was
determined for different surfaces and the stability of the
cytotoxic drugs on the wiping papers was studied. The
method was finally applied for surface contamination deter-
mination at the cytotoxic unit of HUG pharmacy.
LC–MS/MS method
Development and validation of the LC–MS/MS method for
the determination of ten cytotoxic drugs has been reported
elsewhere [23]. The compounds have been selected among
the 20 most prepared cytotoxic drugs at the HUG pharmacy
according to toxicity and analytical considerations. These
compounds are cytarabine, gemcitabine, methotrexate,
etoposide phosphate, cyclophosphamide, ifosfamide, irino-
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Fig 3 Recovery of ten cytotoxic drugs from a stainless steel surface obtained with different wiping papers (Ahlstrom, Texwipe, Whatman)
previously wetted by water during wiping step development
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Fig 4 Wiping step development: recovery of cytotoxic drugs as
function of different wiping solvents (water, FA 0.1%, NaOH 0.01 M,
20% ACN with 0.1% FA, 50% ACN with 0.1% FA and ACN with
0.1% FA). Wiping was performed with Whatman filter paper on
stainless steel surface as described in “Experimental”
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tecan, doxorubicin, epirubicin and vincristine. It can be
noted that with 20% of ACN in the wiping samples,
cytarabine and gemcitabine were not separated by chroma-
tography. The presence of ACN is discussed below, and
time segments had to be modified accordingly (Table 1).
Calibration samples were also prepared in 20% ACN with
FA 0.1%, instead of FA 0.1%. A typical chromatogram,
obtained from the analysis of a calibration sample with
50 ng mL−1 of each analyte and 50 ng mL−1 of the IS in
20% ACN with FA 0.1%, is shown in Fig. 1.
Desorption step development
Desorption of cytotoxic drugs from the filter paper was
performed in PE tubes using 1 mL of the desorption
solution. This small volume allowed obtaining a small
quantity of cytotoxic waste and satisfying quantification
limits (“Quantitative performance of the method applied to
different surfaces”).
Several desorption procedures, including gentle mixing
and ultrasonication for 5 and 20 min, were compared using
FA 0.1% as the desorption solution. Recovery values and
confidence interval were calculated for each assay. As
shown in Fig. 2, cytarabine, gemcitabine, methotrexate,
etoposide phosphate, ifosfamide and cyclophosphamide
were not affected by the desorption procedure and exhibited
recoveries close to 100% in all the tested conditions. For
the four other compounds, ultrasonication for 20 min
improved the desorption rate. In addition, it decreased their
confidence interval (inferior to 10%) compared with
desorption by gentle mixing and ultrasonication for 5 min.
FA 0.1% was first tested to be fully compatible with the
LC–MS/MS method [23], but recoveries of only 50–70%
were obtained for irinotecan, doxorubicin, epirubicin and
vincristine. In order to increase the recovery of these
hydrophobic tested substances, 20% ACN was added.
Hence, recoveries were close to 100% for all compounds
(Fig. 2).
The desorption procedure with 20% ACN, FA 0.1% and
ultrasonication for 20 min was evaluated with three series at
three concentrations (10, 50 and 200 ng mL−1), with four
repetitions each. Concentrations of the desorption samples
were calculated from a calibration model constructed the
same day. Recovery was expressed in per cent as the ratio
between the theoretical and average measured values at each
concentration level. Intermediate precisions were expressed
as relative standard deviation (RSD) of the ratio of the
between-day standard deviation (sR). The sR values were
obtained using ANOVA. Recovery values were between 93%
and 102% and intermediate precision inferior to 8% at 10, 50
and 200 ng mL−1 for all compounds (Table 2). Therefore,
the chosen procedure allowed desorption of the ten
cytotoxic drugs from filter paper with satisfying quantita-
tive performance in the studied concentration range.
Table 3 Quantitative performances of the wiping method for the ten cytotoxic drugs on different surfaces at 0.5 ng cm−2
Surface material Stainless
steel
Polypropylene Polystyrol Glass Latex
gloves
Computer
mouse
Paperboard
Cytarabine Recovery (%) 81 79 76 74 58 69 5
Intermediate precision (%) 8.3 7.8 5.8 7.3 18.0 8.8 2.9
Gemcitabine Recovery (%) 82 79 76 74 59 81 5
Intermediate precision (%) 9.5 8.8 6.0 7.7 15.2 6.4 2.5
Methotrexate Recovery (%) 63 85 75 72 50 64 5
Intermediate precision (%) 9.8 5.1 5.2 6.5 12.8 9.8 3.2
Etoposide phosphate Recovery (%) 45 82 73 68 58 81 5
Intermediate precision (%) 7.8 8.2 10.4 11.7 11.0 22.6 1.9
Ifosfamide Recovery (%) 82 91 79 85 65 98 7
Intermediate precision (%) 10.4 8.2 11.2 11.7 17.0 24.8 2.5
Cyclophosphamide Recovery (%) 86 94 71 80 57 77 5
Intermediate precision (%) 10.8 4.8 10.0 15.3 11.4 20.4 2.5
Irinotecan Recovery (%) 57 84 67 65 27 45 15
Intermediate precision (%) 11.8 11.9 14.5 7.7 11.8 12.0 5.3
Doxorubicin Recovery (%) 46 54 47 53 20 35 9
Intermediate precision (%) 5.1 6.1 10.2 10.6 6.8 12.2 3.7
Epirubicin Recovery (%) 46 58 45 55 16 19 13
Intermediate precision (%) 5.2 6.2 6.0 7.6 5.0 11.1 10.6
Vincristine Recovery (%) 50 55 35 56 27 22 13
Intermediate precision (%) 12.0 11.9 13.3 7.6 13.0 12.3 7.1
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Wiping step development
Several wiping procedures were evaluated, including
different wiping papers and wiping solvents. Wipe sampling
was performed on stainless steel surfaces (10×10 cm) to
compare the different procedures in the same conditions.
Recovery values and confidence interval were calculated
for each wiping procedure.
The tested wiping papers were filter paper fromWhatman,
which have already been successfully used for the desorption
of dried blood spots [24, 25]; filter paper from Ahlstrom; and
wipers from Texwipe. The papers were wetted with water
before wiping. As shown in Fig. 3, the best recovery values
with confidence intervals inferior to 20% were achieved with
filter papers from Whatman. Wipers from Texwipe possessed
slightly inferior recovery values with similar precision than
Whatman papers, but they were not easy to handle for
wiping. Filter papers from Ahlstrom gave much lower
recovery values with higher variability than the other two
papers. Therefore, further experiments were performed with
Whatman filter papers.
Filter papers were wetted with 0.1 mL of different
wiping solutions, i.e. water, NaOH 0.01 M, FA 0.1%, 20%
ACN with 0.1% FA, 50% ACN with 0.1% FA, ACN with
0.1% FA and isopropyl alcohol 70%. As shown in Fig. 4,
NaOH 0.01 M was discarded because etoposide phosphate
was not detected in wiping samples, probably due to its
degradation in basic conditions. Moreover, recovery values
inferior to 20% were obtained for doxorubicin, epirubicin
and vincristine. Addition of FA 0.1% to water increased the
recovery values for gemcitabine, etoposide phosphate,
irinotecan and vincristine; better precision values were
also obtained for most cytotoxic drugs. Therefore, an
acidic wiping solution was selected and different
amounts of ACN (20%, 50% and 100%) were tested.
The addition of an organic solvent was used to reduce
the adsorption of more hydrophobic compounds onto the
surface. However, with amounts of ACN superior to
20%, the papers were not easy to handle anymore,
resulting in an increased confidence interval. The same
phenomenon was also observed with isopropyl alcohol
70% as the wiping solution. The presence of 20% ACN
increased the recovery values, and better precision values
(confidence interval inferior to 20%) were achieved.
To improve the recovery rate, a second wiping with a
new filter paper and a separated desorption procedure was
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Fig 5 Stability data of the ten
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performed on the same surface. Recovery values between 10%
and 15% of the initial spiked amount were found. In addition
with the amount found by the first wiping, the total recovery
values were still inferior to 75% for methotrexate, etoposide
phosphate, irinotecan, doxorubicin, epirubicin and vincristine.
This loss of cytotoxicity might be due to adsorption or
degradation issues. Only cytarabine, gemcitabine, ifosfamide
and cyclophosphamide presented total recovery values be-
tween 90% and 100%. Given the low improvement of
recovery values with a second wiping, only one wipe was
performed in the final procedure and a correcting factor per
compound and surface was determined (see below).
Quantitative performance of the method applied to different
surfaces
Quantitative performance was studied with three indepen-
dent series at three concentrations with three repetitions for
the stainless steel plate and polypropylene infusion bag.
Among the investigated surfaces, these two areas were most
commonly in contact with cytotoxic drugs during the daily
preparation of drug formulations. Concentrations of wiping
samples were calculated from the calibration model
constructed the same day. Recovery was expressed in per
cent as the ratio between the theoretical and average
measured values at each concentration level. Intermediate
precision was expressed as the RSD of the ratio of the
between-day standard deviation (sR). The sR values were
obtained using ANOVA. Surface-dependent correcting
factors for each compound were determined according to
the recovery value. This factor was used to calculate the
surface contamination for real wiping samples.
Constant recovery values were found for 0.1, 0.5 and
2 ng cm−2 (corresponding to 10, 50 and 200 ng mL−1) for all
compounds (data not shown). Therefore, the recovery value
could be considered as independent of the concentration
between 0.1 and 2 ng cm−2. The quantitative performance of
the other surfaces (polystyrol, glass, latex gloves, computer
mouse and coated paperboard) were determined at only one
concentration, i.e. 0.5 ng cm−2 (50 ng mL−1). Awide range of
recoveries (5–98%) were obtained according to the investi-
gated surface and compound (Table 3). In general, wiping of
smooth surfaces, such as stainless steel, polypropylene,
polystyrol and glass, presented higher recovery and smaller
RSD values than irregular surfaces such as latex gloves or
computer mouse. Wiping of coated paperboard was not
successful (recovery values between 5% and 15%), probably
due to the absorption of drugs inside the coated paperboard.
For the other surfaces, most recovery values were superior to
50% and RSD for intermediate precision inferior to 20%. As
expected, some compounds (irinotecan, doxorubicin, epiru-
bicin and vincristine) presented lower recovery values,
probably due to adsorption or degradation issues. T
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Limits of quantification (LOQs) were based on the
validation of the LC–MS/MS [23] method and the
determined correction factor for the wiping procedure.
LOQs for all cytotoxic drugs were set at 10 ng per wiping
sample, or 0.1 ng cm−2.
Stability of cytotoxic drugs on wiping papers
According to the number of wipe samples, the wipe
location and the reduced availability of the LC–MS/MS
instrumentation, storage of filter papers might be very
interesting. Therefore, the stability of cytotoxic drugs on
the filter paper was studied over 3 months at three storage
temperatures (−22, 4 and 25°C) in a light-protected area
(Fig. 5). At 25°C, only ifosfamide was stable for 3 months,
whilst all other drugs presented recoveries inferior to 80%
after 2 months. Concentrations of etoposide phosphate,
doxorubicin, epirubicin and vincristine were already de-
creased to 20% after 1 week. At 4°C, the wiping samples
were stable for 1 week, with at least 80% of the initial
concentration found for all drugs. After 2 months, the
concentrations of doxorubicin, epirubicin and vincristine
were inferior to 50% of the initial amount, and at 3 months,
50% of etoposide phosphate was lost. The other com-
pounds were stable for 3 months at 4°C. However, the best
storage conditions for all drugs were obtained at −22°C: All
cytotoxic drugs presented acceptable recoveries between
90% and 110% after 2 months. After 3 months, values
above 50% were obtained. Therefore, wiping samples could
be kept at −22°C for 2 months until desorption procedure
and LC–MS/MS analysis.
Application to surface contamination at the cytotoxic
production unit of HUG pharmacy
In order to demonstrate the applicability of the developed
method to real samples, the contamination rate of the ten
cytotoxic agents was measured on different places of the
cytotoxic unit at HUG pharmacy. The sample locations
included places in the cytotoxic production area such as
working surfaces, floor in front of the isolator door, and
in the storage and checking room for cytotoxic drugs,
including phone, refrigerator, storage shelves and others
(Table 4). Gemcitabine, ifosfamide and cyclophosphamide
were the most commonly detected drugs. This finding
could be explained by the necessity of the operators to
reconstitute these drugs before dilution, the high pre-
scribed concentrations or the quantity of preparations
during the days before wiping. Most of the contamination
was found inside the isolator, and only some traces of
cytotoxic drugs were outside the production zone (inferior
to LOQ). To reduce contamination inside the isolators,
some actions should be applied, such as more efficient
cleaning procedure with the use of different cleaning
solvents or enhanced cleaning frequency.
Conclusions
A wipe sampling procedure coupled to LC–MS/MS was
developed for the determination of ten cytotoxic drugs on
different surfaces. To the author’s knowledge, this work
describes the first wiping method allowing the simultaneous
quantification of ten cytotoxic drugs from different therapeu-
tic families, with well-established quantitative performance in
terms of recovery and precision. Seven surfaces, the most
commonly encountered in hospital production units, were
investigated, and the recovery values were clearly defined
according to surfaces and compounds. Therefore, this
approach is particularly suitable for environmental monitoring
and can be used to identify exposure of hospital staff who
handles cytotoxic drugs and to validate decontamination
procedures. Finally, the method was successfully applied for
the determination of surface contamination at the cytotoxic
production unit of HUG pharmacy.
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